Home
About Us
Company Profile
HIstory
Culture
Honor
Products
Cardiovascular series
Psychiatry series
Hepatobiliary, Gastroenterology Series
Respiratory series
Anti-infective virus series
Other series
Large Infusion Series
Huabao Tong Series
Active Pharmaceutical Ingredient Series
R&D
Academician Expert Workstation
Medical Research and Industry Alliance
News
General News
Party group dynamics
Employee activity
HR
Talent Strategy
Company recruitment
Contact us
中文版
Date:
29 Aug,2022
5 Month, Acquiring Tangshan Bohai Pharmaceutical Co., Ltd.
Previous page
2009
2004
Next page
Related Recommendations
2023/12/30
2023 Self-Monitoring Public Disclosure for Shangma Park
2023/12/15
Good News | Wanbangde Pharmaceutical Group’s Huperzine A for Treating Myasthenia Gravis Receives U.S. FDA Orphan Drug Designation!
Medication Safety Month | Safe Medication Use, Health for the People—Wanbangde Pharmaceutical Group in Action